S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
S&P 500   4,145.19
DOW   32,803.47
QQQ   321.75
Buffett's firm reports $44B loss but its businesses thrive
Musk says Twitter deal could move ahead with 'bot' info
Dems' climate, energy, tax bill clears initial Senate hurdle
Demand for grocery delivery cools as food costs rise
China July exports rise, with trade surplus at record-high
Shift in war's front seen as ships cleared to leave Ukraine
Dems push Biden climate, health priorities toward Senate OK
NASDAQ:CDMO

Avid Bioservices (CDMO) Stock Forecast, Price & News

$19.36
+0.18 (+0.94%)
(As of 08/5/2022 12:00 AM ET)
Add
Compare
Today's Range
$18.80
$19.52
50-Day Range
$12.06
$20.36
52-Week Range
$11.30
$34.51
Volume
490,530 shs
Average Volume
615,317 shs
Market Capitalization
$1.20 billion
P/E Ratio
10.46
Dividend Yield
N/A
Price Target
$26.67

Avid Bioservices MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
37.7% Upside
$26.67 Price Target
Short Interest
Bearish
9.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.96
Upright™ Environmental Score
News Sentiment
-0.02mentions of Avid Bioservices in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$1.30 M Sold Last Quarter
Proj. Earnings Growth
400.00%
From $0.06 to $0.30 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

75th out of 1,283 stocks

Pharmaceutical Preparations Industry

23rd out of 615 stocks

Avid Bioservices logo

About Avid Bioservices (NASDAQ:CDMO) Stock

Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. The company serves biotechnology and biopharmaceutical industries. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.

Avid Bioservices Stock Up 0.9 %

CDMO Stock opened at $19.36 on Friday. The company has a fifty day moving average price of $16.14 and a 200 day moving average price of $17.27. Avid Bioservices has a 12 month low of $11.30 and a 12 month high of $34.51. The company has a market cap of $1.20 billion, a price-to-earnings ratio of 10.46 and a beta of 2.15. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.38 and a quick ratio of 2.03.

Avid Bioservices (NASDAQ:CDMO - Get Rating) last released its quarterly earnings results on Wednesday, June 29th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.06. Avid Bioservices had a net margin of 106.75% and a return on equity of 19.70%. The firm had revenue of $31.23 million during the quarter, compared to the consensus estimate of $29.20 million. Sell-side analysts expect that Avid Bioservices will post 0.06 earnings per share for the current year.

Analyst Ratings Changes

Separately, Royal Bank of Canada lowered their target price on shares of Avid Bioservices from $32.00 to $22.00 and set an "outperform" rating for the company in a report on Thursday, June 30th. One equities research analyst has rated the stock with a sell rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $26.67.

Insider Activity at Avid Bioservices

In other Avid Bioservices news, Director Richard B. Hancock sold 7,537 shares of the company's stock in a transaction on Monday, June 27th. The shares were sold at an average price of $16.07, for a total transaction of $121,119.59. Following the completion of the transaction, the director now owns 35,201 shares in the company, valued at approximately $565,680.07. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Avid Bioservices news, Director Richard B. Hancock sold 7,537 shares of the company's stock in a transaction on Monday, June 27th. The shares were sold at an average price of $16.07, for a total transaction of $121,119.59. Following the completion of the transaction, the director now owns 35,201 shares in the company, valued at approximately $565,680.07. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard B. Hancock sold 2,463 shares of the company's stock in a transaction on Friday, June 24th. The stock was sold at an average price of $16.02, for a total transaction of $39,457.26. Following the transaction, the director now owns 38,936 shares of the company's stock, valued at approximately $623,754.72. The disclosure for this sale can be found here. Insiders sold a total of 73,196 shares of company stock worth $1,304,059 in the last 90 days. 1.49% of the stock is owned by insiders.

Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Stock News Headlines

Is Avid Bioservices (CDMO) a Great Buy?
Avid Bioservices (NASDAQ:CDMO) Shares Gap Up to $17.52
Avid Bioservices (NASDAQ:CDMO) Trading Down 6.6%
Read How Avid Bioservices Fared In Q4
Avid Bioservices's Earnings Outlook
CDMO Avid Bioservices, Inc.
Avid Bioservices's Earnings: A Preview
See More Headlines

Receive CDMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avid Bioservices and its competitors with MarketBeat's FREE daily newsletter.

CDMO Company Calendar

Last Earnings
6/29/2022
Today
8/07/2022
Next Earnings (Estimated)
9/14/2022
Fiscal Year End
4/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDMO
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.67
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+37.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$127.67 million
Pretax Margin
10.59%

Debt

Sales & Book Value

Annual Sales
$119.60 million
Cash Flow
$0.36 per share
Book Value
$2.83 per share

Miscellaneous

Free Float
60,914,000
Market Cap
$1.20 billion
Optionable
Optionable
Beta
2.15














CDMO Stock - Frequently Asked Questions

Should I buy or sell Avid Bioservices stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Avid Bioservices stock.
View analyst ratings for Avid Bioservices
or view top-rated stocks.

What is Avid Bioservices' stock price forecast for 2022?

3 Wall Street analysts have issued 1-year price objectives for Avid Bioservices' shares. Their CDMO stock forecasts range from $22.00 to $30.00. On average, they expect Avid Bioservices' share price to reach $26.67 in the next year. This suggests a possible upside of 37.7% from the stock's current price.
View analysts' price targets for Avid Bioservices
or view top-rated stocks among Wall Street analysts.

How has Avid Bioservices' stock price performed in 2022?

Avid Bioservices' stock was trading at $29.18 at the start of the year. Since then, CDMO stock has decreased by 33.7% and is now trading at $19.36.
View the best growth stocks for 2022 here
.

When is Avid Bioservices' next earnings date?

Avid Bioservices is scheduled to release its next quarterly earnings announcement on Wednesday, September 14th 2022.
View our earnings forecast for Avid Bioservices
.

How were Avid Bioservices' earnings last quarter?

Avid Bioservices, Inc. (NASDAQ:CDMO) released its quarterly earnings data on Wednesday, June, 29th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of ($0.02) by $0.06. The biopharmaceutical company had revenue of $31.23 million for the quarter, compared to analyst estimates of $29.20 million. Avid Bioservices had a trailing twelve-month return on equity of 19.70% and a net margin of 106.75%.

When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?

Shares of Avid Bioservices reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.

What guidance has Avid Bioservices issued on next quarter's earnings?

Avid Bioservices updated its FY 2023 earnings guidance on Wednesday, July, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $140.00 million-$145.00 million, compared to the consensus revenue estimate of $146.50 million.

What is Roger Lias' approval rating as Avid Bioservices' CEO?

2 employees have rated Avid Bioservices CEO Roger Lias on Glassdoor.com. Roger Lias has an approval rating of 49% among Avid Bioservices' employees. This puts Roger Lias in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Avid Bioservices own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avid Bioservices investors own include Array Technologies (ARRY), Anavex Life Sciences (AVXL), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Micron Technology (MU), QUALCOMM (QCOM), NVIDIA (NVDA), Novavax (NVAX) and Pfizer (PFE).

What is Avid Bioservices' stock symbol?

Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."

Who are Avid Bioservices' major shareholders?

Avid Bioservices' stock is owned by many different institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (3.03%), Geneva Capital Management LLC (2.21%), Redwood Investments LLC (1.43%), Kornitzer Capital Management Inc. KS (1.24%), Sargent Investment Group LLC (1.22%) and Royce & Associates LP (0.53%). Company insiders that own Avid Bioservices stock include Daniel R Hart, Daniel Ryan Hart, Joseph Carleone, Mark R Bamforth, Mark R Bamforth, Mark R Ziebell, Nicholas Stewart Green, Patrick D Walsh and Richard B Hancock.
View institutional ownership trends for Avid Bioservices
.

How do I buy shares of Avid Bioservices?

Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avid Bioservices' stock price today?

One share of CDMO stock can currently be purchased for approximately $19.36.

How much money does Avid Bioservices make?

Avid Bioservices (NASDAQ:CDMO) has a market capitalization of $1.20 billion and generates $119.60 million in revenue each year. The biopharmaceutical company earns $127.67 million in net income (profit) each year or $1.85 on an earnings per share basis.

How many employees does Avid Bioservices have?

Avid Bioservices employs 252 workers across the globe.

How can I contact Avid Bioservices?

Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The official website for Avid Bioservices is www.avidbio.com. The biopharmaceutical company can be reached via phone at (714) 508-6100, via email at sdiaz@vidasp.com, or via fax at 714-838-5817.

This page (NASDAQ:CDMO) was last updated on 8/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.